Tapentadol in cancer pain management: a prospective open-label study - Concepedia

Concepedia

Publication | Open Access

Tapentadol in cancer pain management: a prospective open-label study

DOI Full Paper Access

65

Citations

16

References

2012

Year

Sebastiano Mercadante, Giampiero Porzio, Patrizia Ferrera, Federica Aielli, Claudio Adile, Corrado Ficorella, Alessandra Casuccio

Current Medical Research and Opinion

Abstract

This was an open-label study for exploratory purposes. Data should be confirmed in controlled studies with a larger number of patients.

References

	Year	Citations
pain<i>DETECT</i>: a new screening questionnaire to identify neuropathic components in patients with back pain Rainer Freynhagen, Ralf Baron, Ulrich Gockel, Current Medical Research and Opinion	2006	2.2K
Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial Sherwyn Schwartz, Mila Etropolski, Douglas Y. Shapiro, Current Medical Research and Opinion	2010	256
Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study Robert Buynak, Douglas Y. Shapiro, Akiko Okamoto, Expert Opinion on Pharmacotherapy	2010	250
Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee Marc Afilalo, Mila Etropolski, Brigitte Kuperwasser, Clinical Drug Investigation Pain TherapyHealth SciencesPain MedicinePostoperative Pain ManagementChronic Musculoskeletal Condition	2010	226
Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain James Wild, Stefan Grond, Brigitte Kuperwasser, Pain Practice	2010	181
Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain Wolfgang Schröder, Jean De Vry, Thomas Tzschentke, European Journal of Pain	2010	130
Tapentadol Hydrochloride T.M. Tschentke, Jean De Vry, Rolf Terlinden, Drugs of the Future	2006	120
Can the Spitzer Quality of Life Index help to reduce prognostic uncertainty in terminal care? JM Addington-Hall, L Macdonald, HR Anderson British Journal of Cancer Palliative CareNursingPrognostic EvaluationPrimary CareSpitzer Quality	1990	118
Tapentadol hydrochloride. Analgesic, Mu-opioid receptor agonist, noradrenaline reuptake inhibitor Thomas Tzschentke, J. De-Vry, Rolf Terlinden, Drugs of the Future Molecular PharmacologyPain MedicineMedicineNeuropharmacologyPharmacotherapy	2006	105
Mu-opioid and noradrenergic α2-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats Lucy Bee, Kirsty Bannister, Wahida Rahman, Pain	2010	81

Page 1